title: Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.
abstract: OBJECTIVE
  In patients with preeclampsia maternal plasma concentration of plasminogen activator inhibitor-2 (PAI-2) is reduced. The objective of the study was to determine if the altered levels of PAI-2 precede the onset of the disease.
  
  
  METHODS
  Plasma PAI-2 was measured at 11-13 weeks of gestation in 119 pregnancies that developed preeclampsia, 85 that developed gestational hypertension and 204 controls.
  
  
  RESULTS
  There were no significant differences in PAI-2 between the preeclampsia, gestational hypertension and controls (1.07 MoM, 1.08 MoM and 0.96 MoM).
  
  
  CONCLUSIONS
  The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease.
authors.affiliation: Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London, UK.
authors.forename: Ranjit
authors.initials: R
authors.lastname: Akolekar
authors.forename: Jader De Jesus
authors.initials: Jde J
authors.lastname: Cruz
authors.forename: Jose Maria Perez
authors.initials: JM
authors.lastname: Penco
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Kypros H
authors.initials: KH
authors.lastname: Nicolaides
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000097:blood*; D007118:Immunoassay; D008423:Maternal Age; D017396:Plasminogen Activator Inhibitor 2 / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000097:blood*; D012044:Regression Analysis; D012907:Smoking; D011795:Surveys and Questionnaires
chemical_list: D017396:Plasminogen Activator Inhibitor 2